Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer
The invention provides an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide for treatment of cancer is provided. A method of treating cancer using the IGF-1 receptor ligand carrying a therapeutic radionuclide is also provided. An anti-cancer therapeutic agent containing an IGF-1 receptor ligand linked to a toxin is also provided, as are methods of using the toxin conjugates for treatment of cancer.
1. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide; wherein the ligand is an IGF-1 receptor agonist;
wherein the ligand is a variant IGF-1 protein that has reduced binding affinity for soluble IGF-1 binding proteins; wherein the ligand comprises SEQ ID NO:10.
2. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide; wherein the ligand is an IGF-1 receptor agonist;
wherein the ligand is a variant IGF-1 protein that has reduced binding affinity for soluble IGF-1 binding proteins; wherein the ligand comprises SEQ ID NO:9.
3. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide; wherein the ligand is an IGF-1 receptor agonist;
wherein the ligand is a variant IGF-1 protein that has reduced binding affinity for soluble IGF-1 binding proteins; wherein the ligand comprises SEQ ID NO:2.
4. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide; wherein the ligand is an IGF-1 receptor agonist;
wherein the ligand comprises IGF-2 (SEQ ID NO:8).